Neoantigen-Major Histocompatibility Complex class I complex (NeoAg-MHC I) (NeoAg-MHC I)

Patient-specific peptide antigens bound to MHC class I molecules represent a cornerstone of personalized cancer immunotherapy. These complexes, often referred to as neoantigens, arise from somatic mutations unique to an individual's tumor and are not present in healthy tissue, making them ideal targets for minimizing off-target toxicity (Sahin & Türeci, 2018, Science). Dendritic cells (DCs) play a critical role by capturing these antigens and presenting them via MHC class I molecules to naive CD8+ T cells, a process known as cross-priming (Blass & Ott, 2021, Nature Reviews Clinical Oncology). This interaction triggers a robust and specific cytotoxic T-cell response capable of recognizing and eliminating malignant cells expressing the same neoantigen (Ott et al., 2017, Nature). Therapeutic strategies include mRNA-based vaccines, peptide vaccines, and DC-based vaccines designed to deliver these patient-specific sequences to the immune system (Hu et al., 2021, Nature Medicine). By focusing on the unique genetic landscape of a patient's tumor, these therapies aim to overcome the limitations of traditional treatments and provide a highly specific immune-mediated anti-tumor effect.

Other names

Tumor-specific neoantigen-MHC complexpMHC I complexNeoepitope-HLA complexPersonalized tumor-specific antigenPatient-specific neoantigen-HLA complex

Activation of the adaptive immune system by presenting tumor-specific mutated peptides to the T-cell receptor (TCR) of CD8+ cytotoxic T lymphocytes, leading to targeted destruction of tumor cells.